We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

17 hedge funds and large institutions have $3.13M invested in Galmed Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

27% more capital invested

Capital invested by funds: $2.47M → $3.13M (+$666K)

0% more funds holding

Funds holding: 17 → 17 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

Holders
17
Holders Change
–
Holders Change %
0%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
1
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$597K
2
PAWC
P.A.W. Capital
Connecticut
+$251K
3
VKH
Virtu KCG Holdings
New York
+$69.4K
4
CS
Credit Suisse
Switzerland
+$46K
5
Wells Fargo
Wells Fargo
California
+$31.7K

Top Sellers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
-$224K
2
CAD
Craig A. Drill
-$90K
3
Renaissance Technologies
Renaissance Technologies
New York
-$49K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$23K
5
Deutsche Bank
Deutsche Bank
Germany
-$23K
Name Holding Trade Value Shares
Change 		Change in
Stake
6CM
1
683 Capital Management
New York
$1.4M +$597K +792 +82%
PWAM
2
Park West Asset Management
California
$912K – – –
PAWC
3
P.A.W. Capital
Connecticut
$266K +$251K +333 New
SKK
4
Shepherd Kaplan Krochuk
Massachusetts
$142K – – –
VKH
5
Virtu KCG Holdings
New York
$73K +$69.4K +92 New
WJA
6
Williams Jones & Associates
New York
$67K +$20.4K +27 +48%
MC
7
Menta Capital
California
$65K -$14.3K -19 -19%
CA
8
CapWealth Advisors
Tennessee
$53K – – –
CS
9
Credit Suisse
Switzerland
$49K +$46K +61 New
Morgan Stanley
10
Morgan Stanley
New York
$43K +$19.6K +26 +96%
Wells Fargo
11
Wells Fargo
California
$33K +$31.7K +42 New
UBS Group
12
UBS Group
Switzerland
$17K +$15.8K +21 New
EDRE
13
Edmond de Rothschild (Europe)
Luxembourg
$4K – – –
EDRH
14
Edmond de Rothschild Holding
Switzerland
$4K – – –
Bank of America
15
Bank of America
North Carolina
$2K – – –
RFA
16
Reilly Financial Advisors
California
$1K – – –
AIM
17
Acrospire Investment Management
Illinois
$1K +$754 +1 New
KCM
18
Knoll Capital Management
Florida
– -$224K -277 Closed
CAD
19
Craig A. Drill
– -$90K -111 Closed
Renaissance Technologies
20
Renaissance Technologies
New York
– -$49K -61 Closed
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
– -$23K -29 Closed
Deutsche Bank
22
Deutsche Bank
Germany
– -$23K -29 Closed
TRCT
23
Tower Research Capital (TRC)
New York
– -$1.51K -2 Closed

GLMD Hedge Fund Activity: Q3 2016 in Review

17 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2016, worth a combined $3.13M — up 27% from $2.47M a quarter earlier.

Fund positioning in GLMD was balanced in Q3 2016: 6 funds opened new positions, 6 closed out, 3 added to existing stakes and 1 trimmed.

The largest buyer was 683 Capital Management, adding an estimated $597K. The largest seller was Knoll Capital Management, exiting entirely with an estimated $224K sold.

  • 17 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2016, unchanged from Q2 2016.
  • Funds reported $3.13M of Galmed Pharmaceuticals stock for Q3 2016, up 27% quarter-over-quarter.
  • 6 funds opened new Galmed Pharmaceuticals positions in Q3 2016 and 6 closed out, a net change of 0 holders.
  • The largest Galmed Pharmaceuticals buyer in Q3 2016 was 683 Capital Management, an estimated $597K added.
  • The largest Galmed Pharmaceuticals seller in Q3 2016 was Knoll Capital Management, an estimated $224K sold.

Based on aggregated 13F filings for Q3 2016.